Latest Clinical Trials of AIDS and Hypertension

This article takes stock of the latest AIDS and hypertension research and development pipeline. We counted the data of phase Ⅰ, phase Ⅱ and phase Ⅲ clinical trials of AIDS and hypertension drugs registered on the clinicaltrials.gov. Included in the statistical scope are trials that are in the process of recruitment, recruitment completion and recruitment notices issued, and do not include completed, terminated, unknown, withdrawn and suspended trials.

AIDS Clinical Trial

Human immunodeficiency virus infection and acquired immunodeficiency syndrome (HIV/AIDS) are a series of diseases caused by the human immunodeficiency virus (HIV) infection. As the infection progresses, it interferes more with the immune system, increasing the risk of developing common infections (such as tuberculosis) and other opportunistic infections, as well as tumors in people who rarely affect the normal functioning of the immune system.

As of February 20, 2019, there were 467 clinical trials of new drugs in the field of AIDS, dominated by early clinical studies-174 trials in phase I and 168 trials in phase II, 125 trials in phase III. The research on clinical trials of new AIDS drugs is mainly concentrated in North America and Europe. According to the location of research institutions in clinical trials, the top five countries or regions are 260 in the United States, 63 in South Africa, 49 in France, 48 in Canada and 48 in Spain. The majority of companies that are leading clinical trials of new AIDS drugs are Gilead Science, Mercado and Ferring Pharmaceuticals. The average number of subjects recruited in the clinical trial of new AIDS drugs was 173 in phase 1, 399 in phase 2 and 679 in phase 3, respectively. From January 1 to 31, 2019, there were four newly released clinical trials of new AIDS drugs. Among them, there are 3 in phase Ⅰ and 1 in phase II.

Hypertension

High blood pressure is a common condition in which the long-term force of the blood on the arterial wall is high enough to eventually lead to health problems, such as heart disease. Blood pressure is determined by the amount of blood pumped out of your heart and the resistance to blood flow in your arteries. The more blood your heart pumps in, the narrower the arteries, the higher your blood pressure. You can have high blood pressure for years without any symptoms. Even without symptoms, damage to blood vessels and the heart continues and can be detected. Uncontrolled high blood pressure increases your risk of serious health problems, including heart disease and stroke.As of February 20, 2019, there were 282 clinical trials of new drugs in the field of hypertension, with phase II studies dominating-60 trials in phase I and 124 trials in phase II. There are 98 trials in phase III. The clinical trials of new hypertension drugs are mainly concentrated in North America and Europe. According to the location of research institutions in clinical trials, the top five countries or regions are 159 in the United States, 38 in Germany, 33 in the United Kingdom, 32 in Canada and 30 in France. The companies that are leading the clinical trials of new hypertension drugs are Actelion, United Therapeutics, EMS, Bayer and Chong Kun Dang Pharmaceutical. The average number of subjects recruited in the clinical trial of new hypertensive drugs was 76 in phase I, 143 in phase II and 707 in phase III, respectively. From January 1 to 31, 2019, there were 12 newly released clinical trials of new hypertension drugs. Among them, there are 4 in phase II and 8 in phase III.